The University of Chicago Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of Polley, Mei-Yin
PropertyValue
overview Dr. Polley’s primary research involves the design, conduct, and analysis of all phases of cancer clinical trials. She is the Head of the Statistics Division of NRG Oncology Statistics and Data Management Center (SDMC) as well as the Co-Chair of the Brain Tumor Committee of NRG Oncology, a National Cancer Institute sponsored member of the national clinical trials network group. Previously, she served as the Director of the Biostatistics and Bioinformatics Core of the Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE). Dr. Polley had served on many scientific governing or advisory bodies including the National Cancer Institute Steering Committees (breast, lymphoma, head and neck cancer, and pediatric and adolescent solid tumor), the Scientific Program Committee of American Society of Clinical Oncology (ASCO) annual meetings, and the US Veterans Affairs (VA) Oncology A Study Section. Dr. Polley’s methodological interests include early-phase clinical trial designs, biomarker reproducibility, innovative group sequential methods for biomarker validation, prognostic and predictive modeling, design and analysis of biomarker-based clinical trials, and design and monitoring of late phase clinical trials.
One or more keywords matched the following items that are connected to Polley, Mei-Yin
Item TypeName
Concept Carcinoma, Renal Cell
Concept Carcinoma, Non-Small-Cell Lung
Concept Tumor Stem Cell Assay
Concept Lymphoma, Follicular
Concept Tumor Cells, Cultured
Concept Cell Proliferation
Concept Lymphoma, Large B-Cell, Diffuse
Concept Programmed Cell Death 1 Receptor
Concept Cell Line, Tumor
Concept Cell Survival
Concept Cells, Cultured
Academic Article A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab.
Academic Article Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Academic Article Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.
Academic Article Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Academic Article Two-stage adaptive cutoff design for building and validating a prognostic biomarker signature.
Academic Article Heparan sulfate sulfatase SULF2 regulates PDGFRa signaling and growth in human and mouse malignant glioma.
Academic Article The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias.
Academic Article Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations.
Academic Article Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.
Academic Article Mass Cytometry Analysis Reveals that Specific Intratumoral CD4+ T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma.
Academic Article Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
Academic Article Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era.
Academic Article Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.
Academic Article Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.
Search Criteria
  • Lymphoma
  • Large
  • Cell
  • Anaplastic